Industries > Pharma > Global Treatment for Neglected Tropical Disease Market 2019-2029

Global Treatment for Neglected Tropical Disease Market 2019-2029

Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease

PUBLISHED: 21 May 2019
PAGES: 157
PRODUCT CODE: PHA0396

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0240 Categories: , , Tag:

The Global Treatment for Neglected Tropical Disease market is expected to grow at a CAGR of 7.3% in the second half of the forecast period. The Global Treatment for Neglected Tropical Disease market reached $1.5bn in 2016, dominated by the treatments for malaria which held 30% share of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 71 tables and 80 figures– all unavailable elsewhere.

The 157-page report provides clear detailed insight into the Global Treatment for Neglected Tropical Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Treatment for Neglected Tropical Disease market forecasts from 2019-2029

Global Treatment for Neglected Tropical Disease Market 2017-2027

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by disease type:
– Malaria treatments
– Dengue treatments
– Leishmaniasis
– Schistosomiasis
– Lymphatic Filariasis
– Chagas Disease
– Others

For each disease type, the report provides a SWOT analysis, a list of selected drugs and revenue forecasts from 2019-2029 of the leading drugs.

• This report provides revenue forecast for these leading drugs:
– Coartem (Novartis)
– Clindamycin (Pfizer)
– Dengvaxia (Sanofi)
– AmBisome (Gilead Sciences)
– Impavido (Knight Therapeutics)
– ALBENZA (Amedra Pharmaceuticals LLC)

• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by regional and national market:
– North America: US and Canada
– Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
– Asia-Pacific: Japan, China, India, Rest of Asia
– Latin America: Brazil, Mexico, Rest of Latin America
– Middle East & Africa: Saudi Arabia, South of Africa, Rest of Middle East & Africa

Each regional market is further broken down by disease type.

• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the neglected tropical disease market:
– Pfizer, Inc.
– Bayer
– GlaxoSmithKline plc
– Merck & Co., Inc.
– Novartis International AG
– Takeda Pharmaceutical Company Ltd
– Sanofi S.A.
– Eisai Co., Ltd

Buy our report today Global Treatment for Neglected Tropical Disease Market 2019-2029: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Treatment for Neglected Tropical Disease Market 2019-2029


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category